Theorem Clinical Research

Janssen

Aduro, Johnson & Johnson Innovation and Janssen expand collaboration

Friday, October 17, 2014 12:44 PM

Aduro BioTech, a Berkeley, Calif.-based, private, clinical-stage biotechnology company focused on immunotherapy for cancer, has entered into its second agreement with Janssen Biotech, part of Johnson & Johnson, granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform.

More... »


Bristol-Myers Squibb, Pharmacyclics and Janssen collaborate

Wednesday, October 15, 2014 08:00 PM

Bristol-Myers SquibbPharmacyclics and Janssen R&D have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of BMS’ investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Imbruvica (ibrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen.

More... »


Johnson & Johnson to acquire Alios BioPharma

Wednesday, October 1, 2014 01:04 PM

Johnson & Johnson has announced a definitive agreement to acquire Alios BioPharma, a San Francisco-based, privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.

More... »

Johnson & Johnson to accelerate Ebola vaccine program in collaboration with NIH

Thursday, September 4, 2014 12:29 PM

Johnson & Johnson has committed to accelerate its Ebola vaccine program in collaboration with the NIH. J&J will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate to deliver immediate relief aid to address the current Ebola outbreak.

More... »

Cilag International acquires Covagen

Wednesday, August 27, 2014 01:13 PM

Cilag International, a Switzerland-based affiliate of Janssen Pharmaceutical, a division of Johnson & Johnson, has acquired Covagen, a privately held biopharmaceutical company specializing in the development of multi-specific protein therapeutics through the FynomAb technology platform.

More... »

ViaCyte, Janssen R&D ink agreement

Friday, August 22, 2014 11:54 AM

ViaCyte, a San Diego-based, privately held regenerative medicine company, has entered into a $20 million rights agreement with Janssen R&D, a unit of Johnson & Johnson. The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01 combination product that ViaCyte is developing for type 1 diabetes. This right will continue through the initial evaluation of clinical efficacy of VC-01. 

More... »

Illumina partners with AstraZeneca, Janssen, Sanofi for oncology

Thursday, August 21, 2014 01:42 PM

Illumina, a California-based developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function, has formed collaborative partnerships with AstraZenecaJanssen Biotech and Sanofi to develop a universal next-generation sequencing (NGS)-based oncology test system.

More... »

Pfizer, Roche join ADDPLAN DF Consortium

Monday, August 4, 2014 02:12 PM

Pfizer and Roche have joined the ADDPLAN DF Consortium. The consortium was founded in 2013 by Novartis, Janssen PharmaceuticalsEli Lilly and Aptiv Solutions, an Icon company, to lead the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in phase III trials.

More... »

FDA expands approved use of Imbruvica for CLL

Thursday, July 31, 2014 01:55 PM

The FDA has expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a Breakthrough Therapy Designation for this use.

More... »

ABPI establishes Inward Investor Group

Wednesday, July 23, 2014 10:45 AM

The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating a favorable environment for pharmaceutical companies to invest in the U.K.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs